1-866-735-2792
Talk to a personal injury lawyer.
Raptiva Withdrawn: Patients Die from Fatal Brain Disease, PML
On April 8, 2009, Genentech, the manufacturer of the psoriasis drug Raptiva, announced that it has begun a voluntary, phased out withdrawal from the U.S. market which will be completed by June 8, 2009.
Genentech is taking the action because of a potential risk to patients developing a rare brain disease, progressive multifocal leukoencephalopathy (PML). If you or a loved one has developed PML as a result of being prescribed Raptiva for psoriasis, talk to a product negligence lawyer now about your legal options. One drug prescribed to fix a skin disorder should not create a life threatening health risk.
PML is a rare, serious, progressive neurologic disease caused by a virus that affects the central nervous system. PML is a brain disease that gets worse over time and can attack many parts of the brain at once. There is no effective treatment for PML.
Raptiva warning timeline:
Oct. 16, 2008, FDA updated the FDA-approved labeling for Raptiva to warn of the risk of life-threatening infections, including PML.
Feb. 19, 2009, the FDA issued a Public Health Advisory informing patients and prescribers of the risk of PML in patients taking Raptiva, after receiving reports of four patients with PML, three died.
March 13, 2009, the FDA approved a Medication Guide for Raptiva and included additional information in Raptiva's labeling regarding PML.
Raptiva works by suppressing the immune system to reduce psoriasis flare-ups but by suppressing the body's natural defense system, it can also increase the risk of serious infections and malignancies in patients.
Contact Our Raptiva Lawyers Today »
Which is worse a chronic skin disorder or a fatal brain disease? Do you or a loved one have a PML Raptiva lawsuit? Find out if you are eligible for justice.
